Approval · Notice of Compliance 513 · 2002
FLUOXETINE: Notice of Compliance 513
Issued May 24, 2002
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 513
- Date
- May 24, 2002
- Company
- Pharmel Inc.Montreal, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to an Abbreviated New Drug Submission (SANDS), supplement
- Submission class
- Other
- Reason
- Product monograph update
- Therapeutic class
- Antidepressant, antiobsessional, antibulimic
- Canadian reference product
- PROZAC (Eli Lilly Canada Inc)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| FLUOXETINE | Not yet assigned | — |
Medicinal ingredients
- FLUOXETINE HYDROCHLORIDE 10 MG per CAP
- FLUOXETINE HYDROCHLORIDE 20 MG per CAP